Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics

January 2025 in “ Gels ”

Maryana Salamah, Mária Budai-Szűcs, Bence Sipos, Balázs Volk, Gábor Katona, György Tibor Balogh, Ildikó Csóka

cilostazol spanlastics Phytagel Poloxamer-407 chitosan mucoadhesive properties

The study focused on developing cilostazol-loaded spanlastics (CIL-SPA) for enhanced nose-to-brain delivery, addressing cilostazol's low solubility and absorption issues. The optimized formulations, incorporated into Phytagel®, Poloxamer-407, and chitosan gel bases, demonstrated favorable colloidal properties, high encapsulation efficiency (>99%), and met nasal droplet size requirements. They exhibited strong mucoadhesive properties and significantly improved cilostazol flux and permeability in vitro compared to the initial drug. The formulations released nearly 100% of cilostazol within 2 hours, suggesting their potential to enhance cilostazol's bioavailability for cerebrovascular treatment.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Spanlastic-Laden Nanogel for Dermal Delivery of Bimatoprost in Androgenic Alopecia

March 2024 in “International journal of pharmaceutics. X”

Spanlastic-laden nanogel could be a better way to deliver hair growth medication through the skin for treating hair loss.

research Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines

21 citations , March 2022 in “Pharmaceuticals”

Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

research Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia

19 citations , September 2020 in “Pharmaceutics”

Sodium Valproate nanospanlastics could be a safe and effective treatment for Androgenic Alopecia, with fewer side effects than minoxidil.

Similar Research

5 / 44 results

research The Effect of Cilostazol, a Phosphodiesterase 3 (PDE3) Inhibitor, on Human Hair Growth with Dual Promoting Mechanisms

21 citations , April 2018 in “Journal of Dermatological Science”

Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.

research The Effect of Cilostazol on Hair Growth: A Novel Therapeutic Option for the Treatment of Hair Loss

1 citations , April 2017 in “Journal of Investigative Dermatology”

Cilostazol may help hair grow and could be a new treatment for hair loss.

research Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III

15 citations , November 2002 in “Cardiology in Review”

Cardiovascular drugs can cause various skin problems, so recognizing these reactions is important.

research Comment on ‘Androgenetic Alopecia Is Associated with Increased Scalp Hardness’: Role of Phosphodiesterase Inhibitors?

1 citations , April 2020 in “Journal of The European Academy of Dermatology and Venereology”

Drugs like PDEI may help hair disorders like AGA.

research The Editor's Choice: Summary of Studies on Skin and Hair Conditions

June 2018 in “Journal of Dermatological Science”

UV radiation may cause DNA changes in skin, certain UVB therapy helps psoriasis, a new gene mutation is linked to mild piebaldism, different immune cells affect psoriasis, a drug promotes hair growth, and some cancer drugs could treat skin barrier issues.